Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
Jasper Therapeutics(JSPR) Newsfilter·2024-06-14 12:00| --- | |----------------------------------| | | | Joyce Allaire (investors) | | LifeSci Advisors | | 617-435-6602 | | jallaire@lifesciadvisors.com | | Alex Gray (investors) | | Jasper Therapeutics 650-549-1454 | | agray@jaspertherapeutics.com | | Lauren Walker (media) | | Real Chemistry | | 646-564-2156 | Details of the presentation are below: About Briquilimab Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic ...